Drugs / Brensocatib
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Brinsupri | — | 2025-11-18 | europa.eu ↗ |
| Approved | US (FDA) | BRINSUPRI | — | 2025-08-12 | fda.gov ↗ |
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT06344728 | Apr → May 2024 | — | Insmed Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT06178783 | Dec 2023 → Jan 2024 | — | Insmed Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05965570 | Jul → Sep 2023 | — | Insmed Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05826574 | May → Jul 2023 | — | Insmed Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05517525 | Oct 2022 → Jun 2023 | — | Insmed Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05355935 | Apr → Oct 2022 | — | Insmed Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05652257 | Aug → Sep 2021 | — | Insmed Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05673603 | Jul 2021 → Feb 2023 | impaired renal function disease | Insmed Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05927597 | Jan → Aug 2019 | — | Insmed Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT02653872 | Jan → Apr 2016 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02303574 | Dec 2014 → Aug 2016 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06685835 | Dec 2024 → Feb 2026 | hidradenitis suppurativa | Insmed Incorporated | Terminated | No outcome recorded |
| Phase 2 | NCT06013241 | Oct 2023 → Sep 2025 | chronic rhinosinusitis | Insmed Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT05090904 | Nov 2021 → Nov 2022 | cystic fibrosis | Insmed Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT03218917 | Oct 2017 → Dec 2019 | bronchiectasis | Insmed Incorporated | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04594369 | Dec 2020 → Oct 2024 | bronchiectasis | Insmed Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT04817332 | Jun 2020 → Feb 2021 | COVID-19 | University of Dundee | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05344508 | — | bronchiectasis | Insmed Incorporated | Approved for marketing | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brensocatib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06178783 ↗ |
| Known as | AZD7986 | “Brensocatib (INS1007, formerly AZD7986) is an orally delivered selective, competitive, and reversible inhibitor of DPP1.” NCT04817332 ↗ |
| Known as | INS1007 | “Brensocatib (INS1007) is an oral reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), an enzyme responsible for the activation of neutrophil serine proteases.” PMID 32897034 ↗ Sep 2020 |
| Action | Inhibit | “reversible inhibitor of dipeptidyl peptidase 1 (DPP-1)” PMID 37198686 ↗ May 2023 |
| Modality | Small molecule | — CHEMBL3900409 ↗ |
| Route | Oral | “single and multiple oral doses of AZD7986 in healthy volunteers” NCT02303574 ↗ |
| Target | DPP1 | “inhibitor of dipeptidyl peptidase 1 (DPP-1)” PMID 37198686 ↗ May 2023 |